drugset / Trial / NCT01793259

Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)

NCT01793259 ↗

Phase 3 Completed 120 enrolled medac GmbH
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of this study is to assess the number of patients preferring the methotrexate pre-filled pen to the methotrexate pre-filled syringe after 6 weeks of treatment based on a questionnaire

Timeline

Start
2012-07
Primary completion
2013-04
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 15 mg Subcutaneous
Subject Methotrexate Small molecule 17.5 mg Subcutaneous
Subject Methotrexate Small molecule 20 mg Subcutaneous

Indications